BG
LABD icon

Bellevue Group’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Bellevue Group’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-275
Closed -$1.39M – 220
2019
Q3 		$1.39M Sell
275
-285
-51% -$1.17M 0.03% 132
2019
Q2 		$2.02M Buy
560
+185
+49% +$779K 0.03% 131
2019
Q1 		$1.38M Buy
+375
New +$1.82M 0.08% 118

Other funds holding LABD

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

Bellevue Group's LABD Position: Q4 2019 in Review

Bellevue Group sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q4 2019, closing a stake of 275 shares — an estimated $1.39M sold.

Bellevue Group first reported a position in LABD in Q1 2019 and held it in 3 quarters. The position peaked at $2.02M in Q2 2019. 14 funds tracked by Wall St. Rank hold LABD as of Q4 2019.

  • Bellevue Group reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q4 2019 after selling out during the quarter.
  • Bellevue Group sold 275 Direxion Daily S&P Biotech Bear 3X ETF shares in Q4 2019, an estimated $1.39M.
  • Bellevue Group first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q1 2019 and held it in 3 quarters.
  • Bellevue Group's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $2.02M in Q2 2019.
  • 14 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q4 2019.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.